The FDA rejected an application for the drug MDMA, in combination with therapy, as treatment for PTSD on Friday.

Drugmaker Lykos Therapeutics had asked the FDA to approve its MDMA capsules as part of a therapy regimen they argued could be a breakthrough for treating challenging cases of PTSD. Lykos said the ...

The U.S. Food and Drug Administration (FDA) announced Friday its rejection of MDMA as a treatment for PTSD. The decision was based on "significant limitations" that "prevent the agency from ...

In June, the FDA's Psychopharmacologic Drugs Advisory Committeevoted 9-2 against MDMA as an effective treatment for PTSD patients, and 10-1 that the drug's benefits do not outweigh the risks.

Opens in a new tab or window The FDA declined to approve midomafetamine (MDMA) capsules for post-traumatic stress disorder (PTSD), calling for another trial to evaluate the drug's efficacy and ...

FDA Rejects Psychedelic MDMA as Treatment for PTSD, Calling for Additional Study WASHINGTON (AP) — Federal health regulators on Friday declined to approve the psychedelic drug MDMA as a therapy ...

There are only two FDA-approved treatments for PTSD. MDMA would be the first to come on the market in decades. Though classified as a Schedule I drug, the FDA granted MDMA "breakthrough therapy ...

The Food and Drug Administration declined Friday to approve an application to treat post-traumatic stress disorder using the drug midomafetamine, also known as MDMA or the street drug ecstasy ...

Two small studies submitted to the FDA suggested combining MDMA with talk therapy led to significant easing of PTSD symptoms. Antidepressants are now the only FDA-approved drugs for PTSD ...

MDMA came close to becoming medicine on Friday, but it missed the mark. The Food and Drug Administration declined to approve what would have been the first psychedelic drug used for the treatment ...